Search
# Popular search #
0%
# Popular search #
Stock Code
603087.SHGan & Lee Pharmaceuticals on the official acceptance of the application for listing license of proposed biosimilar insulin lispro injection by the US FDA
Gan & Lee Pharmaceuticals Announces Approval of Insulin Glargine Pre-filled Pen in India
Gan & Lee Pharmaceuticals Announces Approval of Insulin Glargine Injection in Bolivia
The First Chinese Insulin Biologics License Application Submission was Officially Accepted by the US FDA upon the Filing Notification Letter
Gan & Lee Pharmaceuticals Announces Approval of Two Local-filling Insulin Preparations in Indonesia
Great Success! Gan & Lee Exhibited at IDF 2022 World Diabetes Congress
To be a world-class pharmaceutical company with focus on global business development
Our products have been approved in 18 countries
Our products have been exported to 14 countries
Our products have been studied in clinical trials in 12 countries
Our products have been approved in 18 countries
Our products have been exported to 14 countries
Our products have been studied in clinical trials in 12 countries
This website uses cookies to give users like yourself the best possible content and experience. For more information about your choices regarding cookies, please review our Privacy Policy .
The site you are about to visit is maintained by a third party who is responsible for its content.
This link is provided on the Gan & Lee website as a service to our visitors. Gan & Lee is not responsible for the privacy policy of any third-party websites. Gan & Lee encourages visitors to read the privacy policy of every website that you may visit.
